ACT001 Inhibits TLR4 Signaling by Targeting Co-Receptor MD2 and Attenuates Neuropathic Pain

ACT001 Inhibits TLR4 Signaling by Targeting Co-Receptor MD2 and Attenuates Neuropathic Pain

Neuropathic pain is a common and challenging neurological disease, which renders an unmet need for safe and effective new therapies. Toll-like receptor 4 (TLR4) expressed on immune cells in the central nervous system arises as a novel target for treating neuropathic pain. In this study, ACT001, an o...

Full description

Bibliographic Details
Main Authors: Tianshu Zhang, Cong Lin, Siru Wu, Sha Jin, Xiaodong Li, Yinghua Peng, Xiaohui Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
neuropathic pain
toll-like receptor 4
myeloid differentiation protein 2
chronic constriction injury
ACT001
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.873054/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.873054/full

Similar Items